CL2007002668A1 - Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. - Google Patents

Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Info

Publication number: CL2007002668A1
Authority: CL; Chile
Prior art keywords: codifies; understands; joins; diabetes; treat
Prior art date: 2006-09-20

Application number

CL200702668A

Other languages

English (en)

Inventor

Hai Hu Shaw-Fen Sylvia Boo Yan

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2007-09-14

Publication date

2008-05-09

2007-09-14 Application filed by Amgen Inc filed Critical Amgen Inc

2008-05-09 Publication of CL2007002668A1 publication Critical patent/CL2007002668A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Neurology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Mycology (AREA)

CL200702668A 2006-09-20 2007-09-14 Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. CL2007002668A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84620206P	2006-09-20	2006-09-20
US96897707P	2007-08-30	2007-08-30

Publications (1)

Publication Number	Publication Date
CL2007002668A1 true CL2007002668A1 (es)	2008-05-09

Family

ID=39201088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702668A CL2007002668A1 (es)	2006-09-20	2007-09-14	Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Country Status (19)

Country	Link
US (2)	US7947809B2 (es)
EP (1)	EP2074149B1 (es)
JP (1)	JP5513888B2 (es)
KR (1)	KR20090059161A (es)
CN (1)	CN101589062B (es)
AR (1)	AR062895A1 (es)
AU (1)	AU2007297652B2 (es)
BR (1)	BRPI0715017A8 (es)
CA (1)	CA2662613C (es)
CL (1)	CL2007002668A1 (es)
CR (1)	CR10736A (es)
EA (1)	EA200970262A1 (es)
ES (1)	ES2444012T3 (es)
IL (1)	IL197241A0 (es)
MX (2)	MX2009003093A (es)
NO (1)	NO20091534L (es)
PE (1)	PE20080846A1 (es)
TW (1)	TW200820985A (es)
WO (1)	WO2008036341A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR070844A1 (es) *	2008-03-27	2010-05-05	Lilly Co Eli	Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
EP2475683A4 (en) *	2009-09-08	2013-04-24	Neopharm Co Ltd	GLUCAGONIC RECEPTOR ANTIBODY YOUR USE
JO3756B1 (ar)	2010-11-23	2021-01-31	Regeneron Pharma	اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en)	2010-11-23	2014-07-08	Regeneron Pharmaceuticals, Inc.	Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2013059531A1 (en) *	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
JP6050671B2 (ja) *	2012-12-07	2016-12-21	ダイキン工業株式会社	空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
CN105189560A (zh)	2013-05-07	2015-12-23	瑞纳神经科学公司	抗胰高血糖素受体抗体和其使用方法
EP3712166A1 (en)	2013-09-05	2020-09-23	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
ES2772817T3 (es) *	2014-04-10	2020-07-08	Obi Pharma Inc	Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
WO2015175861A1 (en)	2014-05-16	2015-11-19	Amgen Inc.	Assay for detecting th1 and th2 cell populations
EP3151855B1 (en) *	2014-06-08	2021-11-24	REMD Biotherapeutics, Inc.	Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
GB201410826D0 (en) *	2014-06-18	2014-07-30	Bergenbio As	Anti-axl antibodies
RU2021125449A (ru) *	2014-10-01	2021-09-16	Медиммьюн Лимитед	Антитела к тикагрелору и способы применения
CN111018987B (zh) *	2014-12-05	2023-11-21	鸿运华宁（杭州）生物医药有限公司	一种能与人内皮素受体特异性结合的抗体及其应用
EP3236994A1 (en) *	2014-12-23	2017-11-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Alpha-cell re-generation combined with conversion to beta cells
US20160208018A1 (en)	2015-01-16	2016-07-21	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for ror1
CN107614695B (zh) *	2015-04-02	2022-01-25	瑞美德生物医药科技有限公司	用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法
CA2999747A1 (en) *	2015-09-04	2017-03-09	Remd Biotherapeutics, Inc.	Methods for treating heart failure using glucagon receptor antagonistic antibodies
WO2017062693A1 (en) *	2015-10-07	2017-04-13	Remd Biotherapeutics, Inc.	Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
KR101896882B1 (ko)	2015-11-30	2018-09-11	앱클론(주)	Vegfr2에 특이적으로 결합하는 항체
US20190002577A1 (en) *	2016-01-04	2019-01-03	Remd Biotherapeutics, Inc.	Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
MX2019001467A (es) *	2016-08-03	2019-10-02	Remd Biotherapeutics Inc	Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
SG10201913074WA (en)	2016-08-30	2020-03-30	Regeneron Pharma	Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
WO2018075792A1 (en)	2016-10-20	2018-04-26	Regeneron Pharmaceuticals, Inc.	Methods of lowering blood glucose levels
JP7005638B2 (ja)	2017-01-27	2022-02-04	エヌジーエムバイオファーマシューティカルス，インコーポレーテッド	グルカゴン受容体結合タンパク質及びその使用方法
AU2018220734B2 (en) *	2017-02-20	2025-03-06	Dragonfly Therapeutics, Inc.	Proteins binding CD33, NKG2D and CD16
AU2018235928B2 (en)	2017-03-14	2023-09-21	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
CN107011414B (zh) *	2017-05-31	2020-04-24	浙江省农业科学院	具有降血糖功能的三肽spf及其用途
US12139546B2 (en)	2017-08-22	2024-11-12	Regeneron Pharmaceuticals, Inc.	Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
US12325737B2 (en)	2018-03-26	2025-06-10	Amgen Inc.	Total afucosylated glycoforms of antibodies produced in cell culture
CN110357959B (zh) *	2018-04-10	2023-02-28	鸿运华宁（杭州）生物医药有限公司	Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3829636A1 (en)	2018-07-27	2021-06-09	NGM Biopharmaceuticals, Inc.	Use of glucagon receptor antagonists with immunotherapeutic agent
EP3852617B1 (en)	2018-09-20	2025-09-10	SFJ Pharma X, Inc.	Use of antibody fragments for reversing ticagrelor activity
US20220153853A1 (en)	2018-12-21	2022-05-19	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
EP3978527A4 (en) *	2019-05-29	2023-06-14	Hedgehog, Inc.	ANTIBODIES WITH INCREASED BINDING AFFINITY FOR ENDOTHELLIN RECEPTOR A
MX2022001882A (es) *	2019-08-12	2022-05-30	Aptevo Res & Development Llc	Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
KR20220069982A (ko)	2019-09-26	2022-05-27	암젠 인크	항체 조성물의 생산 방법
EP4045515A4 (en)	2019-10-18	2023-10-18	The Regents Of The University Of Michigan	BIOMATERIAL SENSOR SYSTEMS
WO2021247892A1 (en)	2020-06-04	2021-12-09	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3190667A1 (en) *	2020-08-26	2022-03-03	Aaron Sato	Methods and compositions relating to glp1r variants
US20240043501A1 (en)	2020-10-15	2024-02-08	Amgen Inc.	Relative unpaired glycans in antibody production methods
JP2024502035A (ja) *	2020-12-31	2024-01-17	ノヴァロックバイオセラピューティクス，リミテッド	Ｔｎｆｒ２に対する抗体およびそれの使用
WO2022182664A1 (en) *	2021-02-23	2022-09-01	10X Genomics, Inc.	A method for epitope binning of novel monoclonal antibodies
AU2022289365A1 (en)	2021-06-07	2023-12-14	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja)	2021-10-05	2024-10-10	アムジエン・インコーポレーテツド	Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
JP2026516670A (ja)	2023-04-20	2026-05-26	アムジエン・インコーポレーテツド	相対的な不対グリカン含有量を決定する方法
AU2024325342A1 (en)	2023-08-14	2026-02-26	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2026090253A1 (en)	2024-10-23	2026-04-30	Amgen Inc.	Methods of determining glycan pairing content

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5776725A (en) *	1992-08-28	1998-07-07	Zymogenetics, Inc.	Recombinant production of glucagon receptors
US5639863A (en) *	1994-06-21	1997-06-17	Dan; Michael D.	Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5889167A (en) *	1996-05-22	1999-03-30	Merck & Co., Inc.	Synthetic glucagon binding proteins
JP2001206899A (ja) *	1999-11-18	2001-07-31	Japan Tobacco Inc	ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US6909031B2 (en)	2000-12-06	2005-06-21	Deltagen, Inc.	Transgenic mice containing glucagon receptor gene disruptions
US6864069B2 (en)	2001-10-05	2005-03-08	Bayer Pharmaceuticals Corporation	Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
JP4754219B2 (ja) *	2002-12-02	2011-08-24	アムジエン・フレモント・インコーポレイテツド	腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2006005469A2 (en) *	2004-07-15	2006-01-19	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
ZA200705695B (en) *	2004-12-21	2009-02-25	Astrazeneca Ab	Antibodies directed to angiopoietin-2 and uses thereof
EP2361933A3 (en) *	2005-01-26	2012-05-02	Amgen Fremont Inc.	Antibodies against interleukin-1 beta

2007
- 2007-09-14 CL CL200702668A patent/CL2007002668A1/es unknown
- 2007-09-19 EA EA200970262A patent/EA200970262A1/ru unknown
- 2007-09-19 JP JP2009529233A patent/JP5513888B2/ja active Active
- 2007-09-19 CA CA2662613A patent/CA2662613C/en active Active
- 2007-09-19 AR ARP070104134A patent/AR062895A1/es active IP Right Grant
- 2007-09-19 AU AU2007297652A patent/AU2007297652B2/en active Active
- 2007-09-19 MX MX2009003093A patent/MX2009003093A/es active IP Right Grant
- 2007-09-19 ES ES07852417.0T patent/ES2444012T3/es active Active
- 2007-09-19 WO PCT/US2007/020349 patent/WO2008036341A2/en not_active Ceased
- 2007-09-19 CN CN200780042973.XA patent/CN101589062B/zh active Active
- 2007-09-19 MX MX2013003092A patent/MX353319B/es unknown
- 2007-09-19 BR BRPI0715017A patent/BRPI0715017A8/pt not_active Application Discontinuation
- 2007-09-19 TW TW096134772A patent/TW200820985A/zh unknown
- 2007-09-19 EP EP07852417.0A patent/EP2074149B1/en active Active
- 2007-09-19 KR KR1020097007922A patent/KR20090059161A/ko not_active Ceased
- 2007-09-20 PE PE2007001275A patent/PE20080846A1/es not_active Application Discontinuation
- 2007-09-20 US US11/903,481 patent/US7947809B2/en active Active
2009
- 2009-02-25 IL IL197241A patent/IL197241A0/en unknown
- 2009-04-17 CR CR10736A patent/CR10736A/es not_active Application Discontinuation
- 2009-04-17 NO NO20091534A patent/NO20091534L/no not_active Application Discontinuation
2011
- 2011-05-23 US US13/113,996 patent/US8158759B2/en active Active

Also Published As

Publication number	Publication date
US20090041784A1 (en)	2009-02-12
CR10736A (es)	2009-06-30
IL197241A0 (en)	2011-08-01
JP5513888B2 (ja)	2014-06-04
WO2008036341A2 (en)	2008-03-27
EP2074149B1 (en)	2013-11-06
MX353319B (es)	2018-01-05
US7947809B2 (en)	2011-05-24
NO20091534L (no)	2009-04-28
CA2662613A1 (en)	2008-03-27
BRPI0715017A2 (pt)	2013-05-28
EP2074149A2 (en)	2009-07-01
BRPI0715017A8 (pt)	2018-04-03
PE20080846A1 (es)	2008-08-23
ES2444012T3 (es)	2014-02-21
WO2008036341A3 (en)	2009-02-05
US8158759B2 (en)	2012-04-17
JP2010504331A (ja)	2010-02-12
CA2662613C (en)	2014-01-28
US20110223160A1 (en)	2011-09-15
AU2007297652B2 (en)	2012-02-16
CN101589062A (zh)	2009-11-25
AU2007297652A1 (en)	2008-03-27
CN101589062B (zh)	2014-08-20
KR20090059161A (ko)	2009-06-10
AR062895A1 (es)	2008-12-10
TW200820985A (en)	2008-05-16
MX2009003093A (es)	2009-06-05
EA200970262A1 (ru)	2009-10-30

Similar Documents

Publication	Publication Date	Title
WO2008121615A3 (en)	2008-12-04	Antibody formulation
CL2007002070A1 (es)	2008-02-08	Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
CL2013001279A1 (es)	2014-03-07	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
BRPI0715017A8 (pt)	2018-04-03	composições e métodos relativos aos anticorpos receptores de glucagon
IL194550A (en)	2015-06-30	Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
CL2007002767A1 (es)	2008-05-30	Anticuerpo especifico para el receptor ccr5; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar enfermedades inmunosupresoras.
CL2013002062A1 (es)	2014-01-10	Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende: metodo de preparacion; y su uso para estimular la respuesta inmune.
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2007003623A1 (es)	2008-08-08	Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos.
PT2380592T (pt)	2018-06-06	Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
CL2008000935A1 (es)	2008-11-07	Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
CL2013001468A1 (es)	2014-03-21	Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
CL2014001334A1 (es)	2014-12-19	Una proteina de union, anticuerpos o fragmentos del mismo que se une a her-3; molecula de acido nucleico que la codifica; procedimiento de produccion; composicion farmaceutica que lo comprende ; su uso para tratar enfermedades asociadas a her -3; y metodo de diagnostico de una enfermedad (div. sol. 3748-2006).
CL2013001121A1 (es)	2014-03-07	Acido ribonucleico interferente; polinucleotido que lo codifica; construccion de adn que lo codifica; celula huesped; composicion que lo comprende; y su uso para la prevencion y/o control de la infestacion por plaga.
CL2007001840A1 (es)	2008-01-18	Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
CL2009000586A1 (es)	2010-06-04	Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
CL2008000479A1 (es)	2008-08-22	Peptido de glucagon no nativo; composicion farmaceutica que lo comprende; y metodo para tratar la hipoglucemia y diabetes.
CL2007003807A1 (es)	2008-05-09	Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado
CL2008000839A1 (es)	2008-09-26	Anticuerpo anti-ige/m1'; acido nucleico que lo codifica; vector y celula huesped; proceso de produccion; composicion que comprende al anticuerpo; y su uso para tratar trastornos mediados por ige.
CL2007003794A1 (es)	2008-06-27	Anticuerpo anti-receptor del factor de crecimiento insulinico i (igf-ir); polinucleotido que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar cancer.
BRPI0722062A2 (pt)	2014-04-01	Anticorpos contra receptor do fator de crescimento i semelhante à insulina e usos dos mesmos
CL2007002835A1 (es)	2008-05-30	Anticuerpo monoclonal especifico para el receptor cxcr4; acido nucleico que lo codifica; vector y celula que lo comprenden; metodo de produccion; inmunoconjugado y composicion que lo comprende; y su uso para tratar cancer, trastornos inflamatorios y
CL2007003303A1 (es)	2008-06-27	Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2013000843A1 (es)	2014-03-07	Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.